NCT06113198View on ClinicalTrials.gov

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

February 23, 2027

Study Completion Date

July 30, 2027

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

rMenB+OMV NZ

3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.

Trial Locations (10)

6510

RECRUITING

GSK Investigational Site, Incheon

13620

RECRUITING

GSK Investigational Site, Seongnam-si Gyeonggi-do

14068

RECRUITING

GSK Investigational Site, Kyungki-do

54907

RECRUITING

GSK Investigational Site, Jeonju

137701

RECRUITING

GSK Investigational Site, Seoul

400711

RECRUITING

GSK Investigational Site, Junggu

02841

RECRUITING

GSK Investigational Site, Seoul

05505

RECRUITING

GSK Investigational Site, Seoul

07804

RECRUITING

GSK Investigational Site, Seoul

158-710

RECRUITING

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY